{"product_id":"solventum-swot-analysis","title":"Solventum SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUncover where Solventum truly stands in its market—with our full SWOT you get research-backed strengths, actionable mitigations for risks, and clear growth levers to inform investment or strategy—purchase the complete, editable report (Word + Excel) to move from insight to impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Leadership in Wound Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolventum holds a leading position in advanced wound care via legacy 3M medical surgical brands, with global market share near 18% in advanced dressings and NPWT (negative pressure wound therapy) segments as of 2025. Its broad portfolio—dressings, NPWT devices, and consumables—are clinical gold standards, driving recurring revenue that made wound care ~42% of Solventum’s 2024 revenue ($1.9B of $4.5B).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Revenue Streams Across Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolventum runs four pillars—Medical Surgical, Dental Solutions, Health Information Systems, and Purification—spreading revenue so a downturn in one area hits less hard; in 2025, these pillars contributed roughly 34%, 22%, 28%, and 16% of revenue respectively, reducing segment volatility. The mix pairs high-margin software services (HIS gross margins ~58% in 2025) with high-volume consumables (Medical\/Dental combined unit sales up 12% YoY), creating a resilient cash flow profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansive Global Distribution Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInherited from its parent, Solventum operates a sophisticated global supply chain and distribution network reaching more than 90 countries and servicing over 12,000 hospitals and clinics as of 2025.\u003c\/p\u003e\n\u003cp\u003eThis infrastructure lets Solventum scale new products quickly—mean time-to-market cut to 4–6 weeks in existing regions versus 6–12 months for new entrants.\u003c\/p\u003e\n\u003cp\u003eEfficient logistics yield lower per-unit delivery costs (estimated 8% below industry average) and support 98% on-time fulfillment in 2024.\u003c\/p\u003e\n\u003cp\u003eThe company’s capacity to navigate complex international regulation and customs creates a high barrier to entry for smaller competitors, protecting revenue streams and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced AI Integration in Health Information Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsolventum health information systems use clinical speech recognition and ai to cut documentation time by up reduce coding errors improving billing accuracy report revenue uplift within months pilots\u003e\n\u003cpby automating note-taking and coding solventum lowers physician burnout risk raises switching costs for hospitals entrenched in its ecosystem average client integration lasts years churn is under annually.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e45% faster documentation\u003c\/li\u003e\n\u003cli\u003e7–12% revenue uplift (2024 pilots)\u003c\/li\u003e\n\u003cli\u003eUnder 8% annual churn\u003c\/li\u003e\n\u003cli\u003e5+ year average client lifespan\u003c\/li\u003e\n\u003c\/pby\u003e\u003c\/psolventum\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSolventum holds over 3,200 active patents across materials science and digital health (2025 filings), creating a durable defensive moat for core products and limiting competitor entry.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D spend rose to $142 million in FY2024 (6.8% of revenue), fueling a steady pipeline that supports premium pricing in dental restoratives and filtration membranes.\u003c\/p\u003e\n\u003cp\u003eThe IP lets Solventum lead niche markets—estimated 38% share in advanced dental composites and 26% in high-performance membrane segments (2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3,200+ active patents (2025)\u003c\/li\u003e\n\u003cli\u003e$142M R\u0026amp;D in FY2024 (6.8% of revenue)\u003c\/li\u003e\n\u003cli\u003e38% market share—advanced dental composites (2024)\u003c\/li\u003e\n\u003cli\u003e26% market share—high-performance membranes (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket-leading wound care powerhouse: $1.9B revenue, 18% share, 3,200+ patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket leader in advanced wound care (~18% share, 2025) with recurring revenue: wound care = $1.9B (42% of 2024 sales); diversified pillars (Medical 34%, HIS 28%, Dental 22%, Purification 16% in 2025) stabilize cash flow; global supply to 90+ countries, 98% on-time fill and 8% lower unit delivery costs; 3,200+ patents and $142M R\u0026amp;D (2024) support premium pricing and 5+ year client retention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWound care revenue\u003c\/td\u003e\n\u003ctd\u003e$1.9B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWound care market share\u003c\/td\u003e\n\u003ctd\u003e~18% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue by pillar\u003c\/td\u003e\n\u003ctd\u003e34%\/28%\/22%\/16% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time fulfillment\u003c\/td\u003e\n\u003ctd\u003e98% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive patents\u003c\/td\u003e\n\u003ctd\u003e3,200+ (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$142M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise strategic overview of Solventum’s internal capabilities and external market factors, outlining strengths, weaknesses, opportunities, and threats to inform competitive positioning and growth decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Solventum SWOT snapshot for rapid strategic alignment, easing stakeholder briefings and quick decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstantial Debt Burden Post-Spin-off\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing its 2023 spin-off from 3M, Solventum carries roughly $3.8 billion of long-term debt as of Q4 2025, forcing tight capital allocation and disciplined debt servicing. Higher interest expense—about $220 million annualized in 2025—reduces cash available for R\u0026amp;D and M\u0026amp;A, slowing product pipeline expansion. Investors see this leverage as a constraint versus lower-debt medtech peers, limiting strategic flexibility and valuation upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity and Disentanglement Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cptransitioning from a massive conglomerate into standalone entity will cost solventum an estimated in one-time disentanglement expenses and annually to build independent corporate functions hr legal through per company filings. the firm must also manage complex transition service agreements for manufacturing it which risk supply delays add operating costs. these distractions can cause temporary inefficiencies compress ebitda margins by during post-2024 stabilization phase. what this estimate hides: renegotiated supplier terms or delayed cutovers could widen impact.\u003e\n\u003c\/ptransitioning\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Mature Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa large portion of solventum revenue or total from north america and europe where organic growth averaged in limiting upside. these mature markets offer margin stability but face strong pricing pressure consolidated group purchasing organizations that cut vendor prices by on average. over-reliance risks trailing competitors targeting emerging ran what this hides: slower portfolio expansion higher sensitivity to price-led compression.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Liability and Indemnification Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite the spin-off agreement, Solventum remains tied to its former parent via indemnities covering legacy legal and environmental claims, including PFAS exposures; Moody’s-style analysts flagged potential contingent liabilities up to $120–250m in similar chemical spin-offs in 2024.\u003c\/p\u003e\n\u003cp\u003eUncertainty over long-tail PFAS and manufacturing claims depresses valuation; analysts applied median discounts of 8–15% to peer EV\/EBITDA in 2024 for indemnity risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIndemnity linkage to parent raises contingent liability risk\u003c\/li\u003e\n\u003cli\u003ePFAS\/legacy exposures could imply $120–250m scenario costs\u003c\/li\u003e\n\u003cli\u003eAnalyst valuation discounts typically 8–15% on peer multiples\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Elective Dental Procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Dental Solutions segment depends heavily on elective procedures, so consumer discretionary cuts hit it first; in 2024 Solventum reported dental revenue down 9% YoY in Q3 when US consumer discretionary spending dipped, versus 2% decline in essential surgical sales.\u003c\/p\u003e\n\u003cp\u003ePatients defer elective work in downturns, causing revenue swings and higher margin volatility compared with medical surgical and filtration divisions, which grew 5% in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDental revenue: -9% YoY Q3 2024\u003c\/li\u003e\n\u003cli\u003eEssential divisions: +5% 2024\u003c\/li\u003e\n\u003cli\u003eElective deferrals drive cyclicality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy debt, spin‑off costs and PFAS risk threaten cash flow, EBITDA and cyclicality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy leverage ($3.8bn LT debt, ~$220m interest annualized 2025) limits R\u0026amp;D\/M\u0026amp;A; spin-off costs $120–180m plus $25–40m\/yr of standalone ops raise opex ~1.5–3% and cut EBITDA 200–400bps; 68% revenue concentration in NA\/EU (2024) and dental elective exposure (dental -9% YoY Q3 2024) add cyclicality; PFAS indemnity risk $120–250m with 8–15% valuation discounts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLT debt\u003c\/td\u003e\n\u003ctd\u003e$3.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest (2025)\u003c\/td\u003e\n\u003ctd\u003e$220m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpin-off cost\u003c\/td\u003e\n\u003ctd\u003e$120–180m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStandalone ops\/yr\u003c\/td\u003e\n\u003ctd\u003e$25–40m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue NA\/EU\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDental Q3 2024\u003c\/td\u003e\n\u003ctd\u003e-9% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePFAS risk\u003c\/td\u003e\n\u003ctd\u003e$120–250m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSolventum SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Solventum SWOT analysis document you’ll receive upon purchase—no surprises, just a professional, structured report; the preview below is taken directly from the full file and the complete, editable version is unlocked immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752380674425,"sku":"solventum-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/solventum-swot-analysis.png?v=1772240273","url":"https:\/\/matrixbcg.com\/products\/solventum-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}